| Stivarga (regorafenib) / Bayer |
| Completed | 1 | 62 | Europe | Regorafenib (BAY73-4506), Vincristine (Cellcristin®), Irinotecan (Irinotecan Cell pharm®) | Bayer | Pediatric Oncology | 05/19 | 03/24 | | |
NCT03042689: Study of Regorafenib in Patients With Advanced Myeloid Malignancies |
|
|
| Completed | 1 | 16 | US | Regorafenib, Stivarga | Massachusetts General Hospital, Bayer | Acute Myeloid Leukemia | 09/21 | 02/23 | | |
NCT03712943: Regorafenib and Nivolumab in Mismatch Repair (MMR) Refractory Colorectal Cancer |
|
|
| Completed | 1 | 52 | US | Regorafenib, Stivarga, Nivolumab, OPDIVO | H. Lee Moffitt Cancer Center and Research Institute, Bristol-Myers Squibb | Colorectal Cancer, Metastatic Colorectal Cancer, Colon Cancer | 09/21 | 01/24 | | |
NCT06283134: A Clinical Study of BioTTT001 in Combination With Toripalimab and Regorafenib in Patients With Colorectal Cancer |
|
|
| Not yet recruiting | 1 | 40 | NA | BioTTT001 hepatic artery infusion, toripalimab, regorafenib | China Medical University, China, Beijing Bio-Targeting Therapeutics Technology Co., Ltd | Colorectal Cancer Metastatic | 12/27 | 12/27 | | |
REGO-EWING, NCT05830084: Phase Ib / Regorafenib With Conventional Chemotherapy/Newly Diagnosed Patients/ Multimetastatic Ewing Sarcoma |
|
|
| Recruiting | 1 | 24 | Europe | regorafenib tablet | Gustave Roussy, Cancer Campus, Grand Paris, Bayer | Bone Cancer | 03/26 | 03/26 | | |
